p53 Human ELISA Kit (ab46067)
- Product namep53 Human ELISA KitSee all p53 kits ...
Intra-assay Sample n Mean SD CV% A 8 53.6U/ml 1.39 2.6% B 8 14.7U/ml 0.62 4.2% Inter-assay Sample n Mean SD CV% A 5 29.1U/ml 2 6.8% B 4 5.87U/ml 0.55 9.3%
- Tests1 x 96 well plate
- Sample typeCell culture supernatant, Serum, Plasma
- Assay typeSandwich
- Sensitivity< 1.5 U/ml
- Range3.1 U/ml - 100 U/ml
- Assay time3h 45m
- Species reactivityReacts with: Human
- Product overview
Abcam’s p53 Human ELISA kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Human p53 in serum, plasma and cell lysates.
PRINCIPLE OF THE METHOD
The p53 Kit is a solid phase sandwich Enzyme Linked-Immuno- Sorbent Assay (ELISA). A monoclonal antibody specific for p53 has been coated onto the wells of the microtiter strips provided. Samples, including standards of known p53 concentrations and unknowns are pipetted into these wells.
During the first incubation, the p53 antigen is added to wells. After washing, a biotinylated monoclonal antibody specific for p53 is incubated. Then the enzyme ( streptavidin-peroxydase ) is added. After incubation and washing to remove all unbound enzyme, a substrate solution which actes on the bound enzyme is added to induce a coloured reaction product. The intensity of this coloured product is directly proportional to the concentration of p53 present in the samples.
Recognizes both natural and recombinant Human p53 Range: 3.1 U/ml - 100 U/ml Sensitivity
- For research use only.
- The human blood components included in this kit have been tested and found non reactive for HBsAg and anti-HIV. Nevertheless, no known method can offer complete assurance that human blood derivatives will not transmit hepatitis, AIDS or other infections. Therefore, handling of reagents, serum or plasma specimens should be in accordance with local safety procedures , e.g. CDC/NIH Health manual : " Biosafety in Microbiological and Biomedical Laboratories" 1984.
- Avoid any skin contact with H2SO4 and TMB. In case of contact, wash thoroughly with water.
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used.
- Do not pipette by mouth.
- The stop solution in this kit contains 9.8% sulphuric acid.
- Tested applicationsELISA more details
- Storage instructionsStore at +4°C. Please refer to protocols.
Components Identifier 1 x 96 tests 10X Standard Diluent Buffer Black 1 x 25ml 200X Washing Buffer White 1 x 10ml Biotinylated Antibody Diluent Red 1 x 7.5ml Biotinylated anti-p53 antibody Red 1 x 0.4ml Chromogen TMB 1 x 11ml HRP Diluent Red 1 x 23ml p53 Control Silver 2 vials p53 precoated microtiter plates 8 units p53 Standard Yellow 2 vials Standard Diluent (human serum) 1 x 7ml Stop Reagent Black 1 x 11ml Streptavidin-HRP 2 x 5µl
Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980].
Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome.
modificationsAcetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.
Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP.
Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
Sumoylated by SUMO1.
- Antigen NY-CO-13BCC7Cellular tumor antigen p53
- LFS1p53p53 tumor suppressorP53_HUMANPhosphoprotein p53Tp53Transformation related protein 53TRP53Tumor suppressor p53
Our Abpromise guarantee covers the use of ab46067 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
References for p53 Human ELISA Kit (ab46067)
ab46067 has not yet been referenced specifically in any publications.